Comparative Pharmacology
Head-to-head clinical analysis: LABETALOL versus PROPRANOLOL HYDROCHLORIDE HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LABETALOL versus PROPRANOLOL HYDROCHLORIDE HYDROCHLOROTHIAZIDE.
Labetalol vs PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Labetalol is a racemic mixture of four stereoisomers, each with distinct activity. It is a non-selective beta-adrenergic antagonist (blocking beta1 and beta2 receptors) and a selective alpha1-adrenergic antagonist. The alpha1 blockade causes vasodilation and reduces peripheral vascular resistance, while beta blockade reduces heart rate and myocardial contractility, leading to decreased blood pressure without significant reflex tachycardia.
Propranolol is a non-selective beta-adrenergic receptor antagonist blocking beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and renin release; hydrochlorothiazide is a thiazide diuretic inhibiting sodium and chloride reabsorption in the distal convoluted tubule.
Oral: 200-1200 mg/day in 2 divided doses; initial 100 mg twice daily. IV: 20 mg bolus over 2 minutes, may repeat 40 mg at 10-minute intervals. Max cumulative dose: 300 mg.
Propranolol hydrochloride 40-80 mg/hydrochlorothiazide 25-50 mg orally twice daily. Maximum propranolol 640 mg/day, hydrochlorothiazide 50 mg/day.
None Documented
None Documented
Clinical Note
moderateLabetalol + Digitoxin
"Labetalol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateLabetalol + Deslanoside
"Labetalol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateLabetalol + Acetyldigitoxin
"Labetalol may increase the bradycardic activities of Acetyldigitoxin."
Clinical Note
moderateLabetalol + Ouabain
"Labetalol may increase the bradycardic activities of Ouabain."
6-8 hours (terminal elimination half-life); may be prolonged in hepatic impairment, unchanged in renal impairment.
Propranolol: 3-6 hours (terminal half-life); can increase with hepatic impairment. Hydrochlorothiazide: 6-15 hours (terminal half-life); prolonged in renal impairment.
Renal (55-60% as unchanged drug and metabolites); biliary/fecal (minor, approximately 5-10%); remainder metabolized in liver.
Propranolol: <1% excreted unchanged in urine; extensively metabolized in liver, metabolites excreted renally. Hydrochlorothiazide: ≥95% excreted unchanged in urine via renal tubular secretion.
Category A/B
Category C
Alpha/Beta-Blocker
Beta-Blocker